Panel Discussion: Evaluating the Current Landscape of Plasma-Based Markers of β-Amyloid Pathology in Alzheimer’s Disease & Mapping the Path to Widespread Blood Testing
Time: 9:30 am
day: Pre-Conference Day
Details:
- How will the breakthroughs in blood-based amyloid biomarkers advance precision medicine?
- What are the opportunities for these β-amyloid assays to be used commercially to inform patient selection?
- How do we determine the right cut off, based on somebody’s age, gender, or phenotype, to deem a patient amyloid-positive and enrol them?
- Have there been advancements to develop biomarkers to predict who’s going to be at risk of ARIA so we can select against this?
